News from the FDA/CDC

New CDC advisory once again flags BA.2.86 COVID variant


 

An emerging variant of COVID-19 called BA.2.86 that caused alarm in the summer of 2023 has landed on the Center for Disease Control and Prevention’s radar again.

The variant accounted for nearly 9% of cases during the 2-week period ending Nov. 25, up from 3% during the previous 2 weeks, according to data published Nov. 27 by the CDC. The estimates are not exact, and the CDC indicated the actual percentage of cases may range from 5% to 15%.

CDC News icon

The CDC took the unusual step of publishing a specific statement about the rise in BA.2.86 cases. The variant drew worldwide attention during the summer because of how different its makeup is, compared with other prominent variants of the virus that causes COVID-19, raising the potential for the new variant to be more capable of causing infection. But after a flurry of interest in BA.2.86, it didn’t end up being as widespread as expected, so for months it wasn’t listed as a standalone variant on the CDC’s variant tracker list.

“At this time, BA.2.86 does not appear to be driving increases in infections or hospitalizations in the United States,” the CDC wrote in its advisory. “It is not possible at this time to know whether BA.2.86 infection produces different symptoms from other variants. In general, symptoms of COVID-19 tend to be similar across variants. The types of symptoms and how severe they are usually depend more on a person’s immunity than which variant causes the infection.”

BA.2.86 is now the third-most prominent variant circulating the United States, behind HV.1 and EG.5, which combined account for about 45% of all U.S. COVID-19 cases. All three are from the Omicron lineage of the virus.

About 8% of all COVID tests reported to the CDC were positive for the week ending Nov. 18, which is a decline, compared with recent weeks. But indicators for severe cases of the illness have ticked up lately, including rises among ED visits for COVID, hospitalizations, and deaths.

A version of this article appeared on WebMD.com.

Recommended Reading

COVID coronary plaque infection confirms CV risk
MDedge Emergency Medicine
mRNA vaccine cuts COVID-related Guillain-Barré risk
MDedge Emergency Medicine
Nirmatrelvir-ritonavir ineffective at reducing most post-COVID conditions
MDedge Emergency Medicine
Serious mental illness tied to 50% higher all-cause mortality risk after COVID
MDedge Emergency Medicine
Second infection hikes long COVID risk: Expert Q&A
MDedge Emergency Medicine
A new long COVID explanation: Low serotonin levels?
MDedge Emergency Medicine
Sensory comeback: New findings show the path to smell and taste recovery after COVID
MDedge Emergency Medicine
Long COVID and mental illness: New guidance
MDedge Emergency Medicine
AI tool perfect in study of inflammatory diseases
MDedge Emergency Medicine
Unexplained collapse unveils rare blood disorder
MDedge Emergency Medicine